Shield Therapeutics (LSE:STX) Forward Dividend Yield % : 0.00% (As of May. 26, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Forward Dividend Yield %?

As of today (2024-05-26), the Forward Annual Dividend Yield of Shield Therapeutics is 0.00%.

As of today (2024-05-26), the Trailing Annual Dividend Yield of Shield Therapeutics is 0.00%.

LSE:STX's Forward Dividend Yield % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.855
* Ranked among companies with meaningful Forward Dividend Yield % only.

Shield Therapeutics's Dividends per Share for the six months ended in Jun. 2023 was £0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Shield Therapeutics's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Forward Dividend Yield % falls into.

Shield Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Shield Therapeutics (LSE:STX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Shield Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.